Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial

BackgroundRefractory/relapsed acute myeloid leukemia (R/R AML) has unsatisfactory outcomes even after allogeneic hematopoietic stem cell transplantation. Long-term survival is mainly influenced by complete remission (CR) rates after induction therapies.ObjectivesTo investigate CR/CR with incomplete...

Full description

Bibliographic Details
Main Authors: Chengtao Zhang, Da Gao, Xiaohong Wang, Xiuli Sun, Yan Yan, Yan Yang, Jingjing Zhang, Jinsong Yan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
acute myeloid leukemia
refractory and relapsed
bortezomib
homoharringtonine
FLT3 mutation
induction
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1142449/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1142449/full

Similar Items